Results from the TRILUMINATE study, presented this week at EuroPCR 2019 in Paris, suggest Abbott’s minimally invasive tricuspid valve repair system is an effective solution for patients with structural heart disease, reducing the severity of tricuspid regurgitation (TR) in more than 85% of test cases.

The Heart Rhythm Society issued a first-ever consensus statement on the evaluation, risk stratification and management of arrhythmogenic cardiomyopathy at its annual conference in San Francisco this spring.

Coronary artery bypass grafting (CABG) surgery beat out stent placement with percutaneous coronary intervention (PCI) in a recent study of patients with multivessel coronary artery disease. Patients saw lower risks of death, hospital readmission and revascularization with the former procedure.

SCAI has diversified its planning committees and expanded the focus on live cases for its 2019 scientific sessions, says Program Chair Sunil Rao, MD.

The Heart Rhythm Society's 2019 scientific sessions will be held May 8-11 in San Francisco, a venue that enabled the program committee to tap into Silicon Valley’s expertise with digital health, emerging technology and innovation. HRS.19 Program Director Christine Albert, MD, MPH, gave Cardiovascular Business a preview of meeting highlights.

An expert consensus statement published by the Society for Cardiovascular Angiography and Interventions (SCAI) offers guidance for the safe and effective use of patent foramen ovale (PFO) closure devices to prevent recurrent stroke.

The International Contrast Ultrasound Society (ICUS) is again urging the FDA to remove the “black box” warning from ultrasound contrast agent (UCA) labels, following its filing of a September 2018 citizen petition with the federal agency.

The Pascal transcatheter mitral valve repair (TMVR) system has received its CE mark for the treatment of patients with mitral regurgitation, device manufacturer Edwards Lifesciences announced Feb. 19.